Harnessing arginase 2-specific CD8+ T cells to target immunosuppressive cutaneous T-cell lymphoma
This study provides the first evidence that malignant CTCL cells can be targeted by ARG2-specific CD8+ T cells, highlighting ARG2 as a promising immunotherapeutic target in CTCL.
Authors
- Christoffer Dellgren (ORCID: https://orcid.org/0000-0003-4841-5187)
- Thomas Landkildehus Lisle (ORCID: https://orcid.org/0000-0002-6667-7706)
- Shamaila Munir Ahmad (ORCID: https://orcid.org/0000-0001-5176-5212)
- Morten Orebo Holmström (ORCID: https://orcid.org/0000-0002-3764-8578)
- Mads Hald Andersen (ORCID: https://orcid.org/0000-0002-2914-9605)
- Stine Emilie Weis-Banke (ORCID: https://orcid.org/0000-0002-6037-494X)
- Terkild B. Buus (ORCID: https://orcid.org/0000-0001-7180-6384)
- Leon Eyrich Jessen (ORCID: https://orcid.org/0000-0003-2879-2559)
- Özcan Met (ORCID: https://orcid.org/0000-0002-3256-7592)
- Thy Viet Luu (ORCID: https://orcid.org/0000-0002-6243-9006)
- Niels Ødum
Institutions
- University of Copenhagen (DK)
- University of Southern Denmark (DK)
- Odense University Hospital (DK)
- Herlev Hospital (DK)
- Copenhagen University Hospital (DK)
- IT University of Copenhagen (DK)
- Technical University of Denmark (DK)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2025-11-07
- DOI
- https://doi.org/10.1093/bjd/ljaf450
- Primary Topic
- Cutaneous lymphoproliferative disorders research
- Type
- article
- Field-Weighted Citation Impact
- 0.00